Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 2/20 | 0.51 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.45 |
| ▸ | GRM5 | P41594 | 9/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30512305 | 0.83 | BRD4 (0.46) | WNT3AGRM1GRM5BRD4NAMPT | |
| SCHEMBL14926013 | 0.83 | BRD4 (0.46) | WNT3AGRM1GRM5BRD4NAMPT | |
| SCHEMBL31039781 | 0.79 | GRM1 (0.55) | WNT3AGRM1GRM5NAMPTPDK4 | |
| SCHEMBL976835 | 0.79 | GRM1 (0.55) | WNT3AGRM1GRM5NAMPTPDK4 | |
| SCHEMBL29746802 | 0.79 | GRM1 (0.55) | WNT3AGRM1GRM5NAMPTPDK4 | |
| SCHEMBL26222767 | 0.77 | BTK (0.39) | WNT3ANAMPT | |
| SCHEMBL10265021 | 0.76 | ESR2 (0.53) | NAMPT | |
| SCHEMBL26222768 | 0.75 | WNT3A (0.41) | WNT3ABRD4CDK9 | |
| SCHEMBL20266499 | 0.75 | GRM1 (0.64) | WNT3AGRM1GRM5NAMPTPDK4 | |
| SCHEMBL903903 | 0.74 | GRM1 (0.56) | WNT3AGRM1GRM5NAMPTPDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | WNT3A 2959/4885GRM1 2619/4885GRM5 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.